The Platform Technology Designation, which precedes the current FDA leadership, is designed to streamline the drug ...

The lawsuit alleges that HHS leadership knew the records they used to guide their layoff decisions were inaccurate and ...

Genrix’s velinotamig complements Cullinan’s own pipeline, according to William Blair, which added that the deal will put ...

Massachusetts’ life sciences jobs grew by just 0.03% in 2024, according to a new MassBioEd report. Still, the report found ...

Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...

The FDA plans to “rapidly make available” rare disease drugs and make use of surrogate endpoints to get promising medicines ...

A new report from Pitchbook suggests we’re in for a period of more sustainable investing, with VC firms continuing to create ...

Recent decisions to reduce health and science research funding and limit the participation of international students and ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...